stockrow
Friday 6 November 2026
Export MOBI’s income statement to Excel — free account
Mobia Medical, Inc
MOBI Healthcare Medical Devices
Mobia Medical, Inc’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 104.8% from fiscal 2024.
- Revenue
- +175.9%
- EPS
- +96.0%
- Free cash flow
- −18.0%
Quarter to September 2026, against a year earlier
11.12
0.16
−1.42%
Follow MOBI
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+3 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 6.75 | 6.57 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (0.61) | (16.32) | (24.35) | |
P/B ratio |
— | 0.00 | 1.48 | 1.82 | |
Price to Tangible BV |
— | 0.00 | 1.48 | 1.82 | |
EV/Sales |
— | 0.00 | 2.27 | 3.37 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (0.04) | (0.95) | (1.75) | |
EV/FCF |
— | (0.04) | (0.93) | (1.72) | |
Quick Ratio |
3.73 | 5.12 | 12.63 | 11.09 | |
Current Ratio |
4.54 | 6.06 | 13.28 | 11.79 | |
Net Debt/EBITDA |
0.00 | 0.46 | 9.56 | 0.00 | |
Debt/Assets |
14.81% | 65.20% | 3.73% | 0.00% | |
Debt/Equity |
0.25 | 3.99 | 0.04 | — | |
Asset Turnover |
— | 0.00 | 0.39 | 0.47 | |
Operating CF/Net income |
0.00 | 1.00 | 0.74 | 0.75 | |
Capex/Depreciation |
(1.94) | (0.23) | (9.81) | 0.00 | |
Interest Coverage |
— | (47.44) | (70.57) | (72.11) | |
Research and Development Expense of Revenue |
— | 14.01% | 16.87% | 16.32% | |
Selling, General and Administrative Expense of Revenue |
— | 208.60% | 199.08% | 185.60% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 3.37% | 11.90% | 16.41% | |
Graham Net Nets |
— | 0.94 | 0.66 | 0.49 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (341.88%) | (341.88%) | (353.00%) | |
Free Cash Flow Yield |
— | (783.22%) | (35.98%) | (29.88%) | |
Revenue per Share |
— | 13.14 | 0.71 | 0.47 | |
Operating CF per Share |
0.00 | (19.29) | (0.82) | (0.39) | |
Capex per Share |
0.00 | (0.05) | (0.08) | 0.00 | |
Free Cash Flow per Share |
0.00 | (19.34) | (0.90) | (0.39) | |
Cash per Share |
0.00 | 60.64 | 9.28 | 4.83 | |
Shareholders Equity per Share |
0.00 | 13.08 | 9.04 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 13.08 | 9.04 | 0.00 | |
Free Cash Flow |
(46.06) | (17.77) | (17.21) | (12.98) | |
Working Capital |
36.15 | 59.88 | 177.68 | 163.11 | |
Capital Expenditures |
(0.36) | (0.04) | (1.54) | (0.06) | |
Net Current Asset Value |
27.21 | 10.14 | 169.47 | 154.97 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.11 | 0.00 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 4.92 | |
Average Payables |
— | — | — | 2.22 | |
Average Inventory |
— | — | — | 5.89 | |
Average Assets |
— | 47.84 | 97.64 | 101.63 |
Columns are period end dates · fundamentals updated 5 Nov 2026